The Trump administration finalized GLOBE, a mandatory pilot tying Medicare prices for doctor-administered drugs to those in other wealthy countries. Exemptions for companies with voluntary pricing deals and for rare-disease drugs leave only four companies covered, cutting projected savings by 96%.